ZNTLZentalis Pharmaceuticals, Inc.
3.825USD-0.39%Mkt Cap: 362.12M $P/E: —3d ago
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenose…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
Sector Update: Healthcare Stocks Decline Late Afternoon Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.4% a | MMT Newswires | |
 ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally? Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian cancer program. | ||